Newleos Therapeutics, Inc. is a pioneering clinical-stage neuroscience company focused on the innovation of therapies for neuropsychiatric disorders. With a commitment to addressing the pressing unmet needs in mental health, Newleos is dedicated to developing effective tools for anxiety and substance use disorders, impacting millions across the United States.
NTX-1955 is a groundbreaking GABA A -γ1 selective positive allosteric modulator that represents the company's lead clinical program aimed at treating anxiety disorders. This molecule is designed to help mitigate anxiety symptoms with potentially fewer side effects compared to traditional therapies.
NTX-1955 aims to provide patients suffering from anxiety disorders with a safer and more effective treatment alternative that addresses the limitations of existing therapies.
Patients experience challenges such as ineffective treatment options, adverse side effects from current therapies, and the need for safer, more effective management of their conditions.